Volume 27, Number 2—February 2021
Research
Increasing Incidence of Invasive Group A Streptococcus Disease in First Nations Population, Alberta, Canada, 2003–2017
Table 1
System, clinical condition | First Nations, no. (%) cases | Non–First Nations, no. (%) cases | p value† |
---|---|---|---|
Blood, brain, sterile tissue | |||
Septicemia/bacteremia | 319 (37.8) | 1570 (42.8) | 0.011 |
Streptococcal toxic shock syndrome | 19 (2.3) | 235 (6.4) | <0.001 |
Meningitis | 9 (1.1) | 16 (0.4) | 0.061 |
Peritonitis | 5 (0.6) | 24 (0.7) | 0.886 |
Encephalitis |
1 (0.1) |
0 |
0.373 |
Skin/soft tissue | |||
Cellulitis | 146 (17.3) | 633 (17.3) | 0.971 |
Soft tissue infection | 159 (18.8) | 397 (10.8) | <0.001 |
Necrotizing fasciitis |
60 (7.1) |
266 (7.3) |
0.989 |
Respiratory | |||
Pneumonia | 50 (5.9) | 291 (7.9) | 0.054 |
Epiglottitis |
2 (0.2) |
11 (0.3) |
0.824 |
Bone | |||
Joint | 63 (7.5) | 192 (5.2) | 0.016 |
Osteomyelitis |
10 (1.2) |
27 (0.8) |
0.272 |
Unknown |
2 (0.2) |
0 |
0.069 |
Total | 845 (100) | 3,688 (100) | Not applicable |
*Patients may have multiple clinical manifestations (193 patients had 2 clinical manifestations, 39 patients had 3, 2 patients had 4, and 1 had 5). †By Fisher exact test.
Page created: December 07, 2020
Page updated: January 23, 2021
Page reviewed: January 23, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.